Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array‐CGH interpretation

Quitterie Fontanges,Paul Dubos,Tom Lesluyes,Yec'han Laizet,Valérie Velasco,Bárbara Meléndez,Nicky D'Haene,Esther Oliva,Robert H. Young,Laetitia Mayeur,Flora Rebier,Mélissa Alamé,Claire Larmonier,Mojgan Devouassoux‐Shisheboran,Laurent Arnould,Isabelle Soubeyran,Camille Chakiba,Anne Floquet,Guillaume Babin,Frédéric Guyon,Eliane Mery,Sophie Le Guellec,Jean‐Christophe Noël,Sabrina Croce,Frédéric Chibon
DOI: https://doi.org/10.1002/gcc.23229
2024-03-15
Genes Chromosomes and Cancer
Abstract:A close relationship has been demonstrated between genomic complexity and clinical outcome in uterine smooth muscle tumors. We studied the genomic profiles by array‐CGH of 28 fumarate hydratase deficient leiomyomas and 37 leiomyomas with bizarre nuclei (LMBN) from 64 patients. Follow‐up was available for 46 patients (from three to 249 months, mean 87.3 months). All patients were alive without evidence of disease. For 51 array‐CGH interpretable tumors the mean Genomic Index (GI) was 16.4 (median: 9.8; from 1 to 57.8), significantly lower than the mean GI in LMS (mean GI 51.8, p 10 or alteration in tumor suppressor genes, should not alone warrant a diagnosis of malignancy. Nine tumors were tested with Nanocind CINSARC® signature and all were classified in low risk of recurrence. We propose, based on our observations, a diagnostic approach of these challenging lesions.
oncology,genetics & heredity
What problem does this paper attempt to address?